البلد: المملكة المتحدة
اللغة: الإنجليزية
المصدر: MHRA (Medicines & Healthcare Products Regulatory Agency)
Dipyridamole
Boehringer Ingelheim Ltd
B01AC07
Dipyridamole
200mg
Modified-release capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02090000; GTIN: 5012816070271
PACKAGE LEAFLET: INFORMATION FOR THE USER: PERSANTIN ® RETARD 200MG CAPSULES (dipyridamole) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. The name of your medicine is Persantin Retard 200mg Capsules, but it will be referred as Persantin Retard throughout this leaflet. IN THIS LEAFLET: 1. What Persantin Retard is and what it is used for 2. Before you take Persantin Retard 3. How to take Persantin Retard 4. Possible side effects 5. How to store Persantin Retard 6. Further information 1. WHAT PERSANTIN RETARD IS AND WHAT IT IS USED FOR The name of your medicine is Persantin Retard. It contains a medicine called Dipyridamole. This belongs to a group of medicines called ‘anti-thrombotic agents’, which are used to help stop blood clots forming. Persantin Retard is used: To help stop blood clots which may occur if you have had your heart valves replaced. In people who have had a stroke caused by a blood clot in the brain. This medicine reduces the risk of having another stroke. 2. BEFORE YOU TAKE PERSANTIN RETARD DO NOT TAKE PERSANTIN RETARD IF YOU ARE ALLERGIC (HYPERSENSITIVE) TO: Dipyridamole Any of the other ingredients of Persantin Retard (see section 6: ‘Further Information’) TAKE SPECIAL CARE WITH PERSANTIN RETARD Check with your doctor or pharmacist before taking your medicine if: You have angina or other heart problems (including heart valve or circulation problems) or have had a recent heart attack You have myasthenia gravis (a rare muscle problem) You have any bleeding problems You are pregnant or planning to become pregnant or are breast-feeding If you are not sure if any اقرأ الوثيقة كاملة
OBJECT 1 PERSANTIN RETARD 200 MG Summary of Product Characteristics Updated 02-Mar-2015 | Boehringer Ingelheim Limited 1. Name of the medicinal product Persantin ® Retard 200 mg Modified Release Capsules, Hard 2. Qualitative and quantitative composition Each modified release capsule contains dipyridamole 200 mg. For excipients, see 6.1 3. Pharmaceutical form Modified release capsules, hard. Hard gelatin capsules consisting of a red cap and an orange body. 4. Clinical particulars 4.1 Therapeutic indications - Secondary prevention of ischaemic stroke and transient ischaemic attacks either alone or in conjunction with aspirin. - An adjunct to oral anti-coagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. 4.2 Posology and method of administration For oral administration. Adults, including the elderly The recommended dose is one capsule twice daily, usually one in the morning and one in the evening preferably with meals. The capsules should be swallowed whole without chewing. Children PERSANTIN Retard 200 mg is not recommended for children. 4.3 Contraindications Hypersensitivity to any component of the product. 4.4 Special warnings and precautions for use Among other properties, dipyridamole acts as a potent vasodilator. It should therefore be used with caution in patients with severe coronary artery disease including unstable angina and/or recent myocardial infarction, left ventricular outflow obstruction or haemodynamic instability (e.g. decompensated heart failure). Patients being treated with regular oral doses of PERSANTIN Retard should not receive additional intravenous dipyridamole. Clinical experience suggests that patients being treated with oral dipyridamole who also require pharmacological stress testing with intravenous dipyridamole, should discontinue drugs containing oral dipyridamole for twenty-four hours prior to stress testing. In patients with myasthenia gravis readjustment of therapy may be necessary after changes in dipyridamole dosage. (See Interactions). PERSAN اقرأ الوثيقة كاملة